Acta Parasitologica

, Volume 64, Issue 4, pp 710–719 | Cite as

Characterization of Transplasma Membrane Electron Transport Chain in Wild and Drug-Resistant Leishmania donovani Promastigote and Amastigote

  • Dipti Debnath
  • Md Akil HossainEmail author
  • Munny Das
  • Asma Kabir
  • Md Ibrahim
  • Mohammad Nurul Amin
  • Amrita Chowdhury
  • Rokeya Pervin
Original Paper



Leishmania donovani (L. donovani) is one of the parasites that cause leishmaniasis. The mechanisms by which L. donovani fights against adverse environment and becomes resistant to drugs are not well understood yet.


The present study was designed to evaluate the effects of different regulators on the modulation of Transplasma Membrane Electron Transport (transPMET) systems of susceptible and resistant L. donovani cells.

Materials and Methods

Effects of UV, different buffers, and electron transport inhibitors and stimulators on the reduction of α-lipoic acid (ALA), 1,2-naphthoquinone-4-sulphonic acid (NQSA) and ferricyanide were determined.

Results and Discussion

ALA reductions were inhibited in susceptible, sodium antimony gluconate (SAG)-resistant and paromomycin (PMM)-resistant AG83 amastigote cells, and stimulated in susceptible and SAG-resistant AG83 promastigote cells upon UV exposure. The results indicate that UV irradiation almost oppositely affect ALA reductions in amastigotes and promastigotes. ALA reductions were stimulated in sensitive and inhibited in resistant GE1 amastigotes upon UV exposure. Susceptible amastigotes and promastigotes inhibited, and resistant amastigotes and promastigotes stimulated NQSA reduction under UV irradiation. Thus, susceptible and drug-resistant amastigotes and promastigotes are different in the reduction of ALA. Susceptible and resistant AG83 amastigotes and promastigotes inhibited the ferricyanide reductions upon UV exposure, which indicates, there is no such difference in ferricyanide reductions among susceptible as well as resistant AG83 amastigotes and promastigotes. The reductions of extracellular electron excerptors in susceptible promastigotes requires the availability of Na+ and Cl ions for maximal activity but susceptible amastigotes are mostly not dependent on the availability of Na+ and Cl ions. Both in promastigotes and amastigotes, reductions of electron acceptors were strongly inhibited by carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone. Furthermore, antimycin A, rotenone and capsaicin markedly inhibited the reductions of electron acceptors in promastigotes, but not in amastigotes.


Results of this study suggest that the transPMET system is functionally different in wild and resistant strains of L. donovani.


L. donovani Electron acceptors Inhibitors and Stimulators 



This research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

None of the authors have any conflicts of interest to declare.

Supplementary material

11686_2019_50_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 24 kb)


  1. 1.
    Bera T, Lakshman K, Ghanteswari D, Pal S, Sudhahar D, Islam MN et al (2005) Characterization of the redox components of transplasma membrane electron transport system from Leishmania donovani promastigotes. Biochim Biophys Acta 1725:314–326. CrossRefPubMedGoogle Scholar
  2. 2.
    Reddy GS, Mukhopadhyay AG, Dey CS (2017) Characterization of ciliobrevin a mediated dynein ATPase inhibition on flagellar motility of Leishmania donovani. Mol Biochem Parasitol 214:75–81. CrossRefPubMedGoogle Scholar
  3. 3.
    Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW et al (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5:873–882. CrossRefPubMedGoogle Scholar
  4. 4.
    Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E et al (1999) Evidence that the high incidence of treatment failures in Indian Kala-Azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180:564–567. CrossRefPubMedGoogle Scholar
  5. 5.
    Selvapandiyan A, Duncan R, Mendez J, Kumar R, Salotra P, Cardo LJ et al (2008) A Leishmania minicircle DNA footprint assay for sensitive detection and rapid speciation of clinical isolates. Transfusion 48:1787–1798. CrossRefPubMedGoogle Scholar
  6. 6.
    Herwaldt BL (1999) Leishmaniasis. Lancet 354:1191–1199. CrossRefPubMedGoogle Scholar
  7. 7.
    WHO (2018) Leishmaniasis. World Health Organization, GenevaGoogle Scholar
  8. 8.
    Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27:305–318. CrossRefPubMedGoogle Scholar
  9. 9.
    Selvapandiyan A, Dey R, Gannavaram S, Lakhal-Naouar I, Duncan R, Salotra P et al (2012) Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites. J Trop Med. CrossRefPubMedGoogle Scholar
  10. 10.
    Singh N (2006) Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian J Med Res 123:411–422PubMedGoogle Scholar
  11. 11.
    Croft SL, Coombs GH (2003) Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19:502–508. CrossRefPubMedGoogle Scholar
  12. 12.
    Forestier C-L, Machu C, Loussert C, Pescher P, Späth GF (2011) Imaging host cell-leishmania interaction dynamics implicates parasite motility, lysosome recruitment, and host cell wounding in the infection process. Cell Host Microbe 9:319–330CrossRefGoogle Scholar
  13. 13.
    Handman E, Bullen DVR (2002) Interaction of leishmania with the host macrophage. Trends Parasitol 18:332–334. CrossRefPubMedGoogle Scholar
  14. 14.
    Wyllie S, Cunningham ML, Fairlamb AH (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279:39925–39932. CrossRefPubMedGoogle Scholar
  15. 15.
    Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL (2012) Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist 2:11–19. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hammarton TC, Mottram JC, Doerig C (2003) The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation. Prog Cell Cycle Res 5:91–101PubMedGoogle Scholar
  17. 17.
    Muylder GD, Ang KKH, Chen S, Arkin MR, Engel JC, McKerrow JH (2011) A screen against leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis 5:e1253. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pearson RD, Harcus JL, Symes PH, Romito R, Donowitz GR (1982) Failure of the phagocytic oxidative response to protect human monocyte derived macrophages from infection by Leishmania donovani. J Immunol 129:1282–1286PubMedGoogle Scholar
  19. 19.
    Croft SL, Neal RA, Pendergast W, Chan JH (1987) The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 36:2633–2636. CrossRefPubMedGoogle Scholar
  20. 20.
    WHO (2010) Control of the leishmaniases. Technical report series, 12–13. World Health Organization, Geneva, pp 1–186Google Scholar
  21. 21.
    Murray HW (1981) Interaction of leishmania with a macrophage cell line. Correlation between intracellular killing and the generation of oxygen intermediates. J Exp Med 153:1690–1695CrossRefGoogle Scholar
  22. 22.
    Murray HW (1986) Cellular resistance to protozoal infection. Annu Rev Med 37:61–67. CrossRefPubMedGoogle Scholar
  23. 23.
    Chang KP, Fong D, Bray RS (1985) Immunodiagnosis of Leishmaniasis. In: Chang KP, Bray RS (eds) Leishmaniasis. Elsevier Biomedical Press, Amsterdam, pp 1–30Google Scholar
  24. 24.
    Dow JA (1992) pH gradients in Lepidopteran midgut. J Exp Biol 172:355–375PubMedGoogle Scholar
  25. 25.
    Rivas L, Chang KP (1983) Intraparasitophorous vacuolar pH of Leishmania mexicana infected macrophages. Biol Bull 165:536–637Google Scholar
  26. 26.
    Blum JJ (1993) Intermediary metabolism of Leishmania. Parasitol Today 9:118–122. CrossRefPubMedGoogle Scholar
  27. 27.
    McLoughlin PM, Sun IL, Crane FL (1984) Adriamycin effects on transplasma membrane redox functions in porcine neutrophils. Biochem Biophys Acta 802:71–76. CrossRefPubMedGoogle Scholar
  28. 28.
    Sun IL, Crane FL, Chou JY, Löw H, Grabbing C (1983) Transformed liver cells have modified transplasma membrane redox activity which is sensitive to Adriamycin. Biochem Biophys Res Commun 116:210–216. CrossRefPubMedGoogle Scholar
  29. 29.
    Sun IL, Crane FL, Grebing C, Löw H (1984) Properties of a transplasma membrane electron transport system of heLa cells. J Bioenerg Biomembr 16:583–595. CrossRefPubMedGoogle Scholar
  30. 30.
    Datta G, Bera T (2002) Transplasma membrane electron transport in Leishmania donovani promastigotes. J Eukaryot Microbiol 49:24–29. CrossRefPubMedGoogle Scholar
  31. 31.
    Ly JD, Lawen A (2003) Transplasma membrane electron transport: enzymes involved and biological function. Redox Rep 8:3–21. CrossRefPubMedGoogle Scholar
  32. 32.
    Kar K, Mukerji K, Naskar K, Bhattacharya A, Ghosh DK (1990) Leishmania donovani: a chemically defined medium suitable for cultivation and cloning of promastigotes and transformation of amastigotes to promastigotes. J Eukaryot Microbiol 37:277–279. CrossRefGoogle Scholar
  33. 33.
    Sereno D, Lemesre JL (1997) Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 41:972–976CrossRefGoogle Scholar
  34. 34.
    Chakraborty B, Biswas S, Mondal S, Bera T (2010) Stage specific developmental changes in the mitochondrial and surface membrane associated redox systems of Leishmania donovani promastigote and amastigote. Biochemistry (Moscow) 75:494–504. CrossRefGoogle Scholar
  35. 35.
    Debrabant A, Joshi MB, Pimenta PFP, Dwyer DM (2004) Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int J Parasitol 34:205–217. CrossRefPubMedGoogle Scholar
  36. 36.
    Ephros M, Waldman E, Zilberstein D (1997) Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob Agents Chemother 41:1064–1068CrossRefGoogle Scholar
  37. 37.
    Saar Y, Ransford A, Waldman E, Mazareb S, Amin-Spector S, Plumblee J (1998) Characterization of developmentally-regulated activities in axenic amastigotes of Leishmania donovani. Mol Biochem Parasitol 95:9–20. CrossRefPubMedGoogle Scholar
  38. 38.
    Merrill AH, Jones DD Jr (1990) An update of the enzymology and regulation of sphingomyelin metabolism. Biochem Biophys Acta 1044:1–12. CrossRefPubMedGoogle Scholar
  39. 39.
    Jhingran A, Chawla B, Saxena S, Barrett MP, Madhubala R (2009) Paromomycin: uptake and resistance in Leishmania donovani. Mol Biochem Parasitol 164:111–117. CrossRefPubMedGoogle Scholar
  40. 40.
    Iovannisci DM, Ullman B (1983) High efficiency plating method for Leishmania promastigotes in semi-defined or completely-defined medium. J Parasitol 69:633–636. CrossRefPubMedGoogle Scholar
  41. 41.
    Das S, Roy P, Mondal S, Bera T, Mukherjee A (2013) One pot synthesis of gold nanoparticles and application in chemotherapy of wild and resistant type visceral leishmaniasis. Colloids Surf B 107:27–34. CrossRefGoogle Scholar
  42. 42.
    Kar N, Chakraborty S, De AK, Ghosh S, Bera T (2017) Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes. Eur J Pharm Sci 104:196–211. CrossRefPubMedGoogle Scholar
  43. 43.
    Mondal S, Roy P, Das S, Halder A, Mukherjee A, Bera T (2013) In vitro susceptibilities of wild and drug resistant Leishmania donovani amastigote stages to andrographolide nanoparticle: role of vitamin E derivative TPGS for nanoparticle efficacy. PLoS One 8:e81492CrossRefGoogle Scholar
  44. 44.
    Huber W, Koella JC (1993) A comparison of the methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop 55:257–261. CrossRefPubMedGoogle Scholar
  45. 45.
    Biswas S, Haque R, Bhuyan NR, Bera T (2008) Participation of chlorobiumquinone in the transplasma membrane electron transport system of Leishmania donovani promastigote: effect of near-ultraviolet light on the redox reaction of plasma membrane. Biochem Biophys Acta 1780:116–127. CrossRefPubMedGoogle Scholar
  46. 46.
    Gornall AG, Bardawill CJ, David MM (1949) Determination of serum proteins by means of the biuret reaction. J Biol Chem 177:751–766PubMedPubMedCentralGoogle Scholar
  47. 47.
    Avron M, Shavit N (1963) A sensitive and simple method for determination of ferrocyanide. Anal Biochem 6:549–554. CrossRefPubMedGoogle Scholar
  48. 48.
    Datta G, Bera T (2001) Evidence for the extracellular reduction of α-lipoic acid by Leishmania donovani promastigotes: a transplasma membrane redox system. Biochem Biophys Acta 1512:149–157. CrossRefPubMedGoogle Scholar
  49. 49.
    Brodie AF, Ballantine J (1960) Oxidative phosphorylation in fractionated bacterial systems. II. The role of vitamin K. J Biol Chem 235:226–231PubMedGoogle Scholar
  50. 50.
    Vieira L, Slotki I, Cabantchik ZI (1995) Chloride conductive pathways which support electrogenic H+ pumping by Leishmania major promastigotes. J Biol Chem 270:5299–5304. CrossRefPubMedGoogle Scholar
  51. 51.
    Navas P, Sun IL, Morré DJ, Crane FL (1986) Decrease of NADH in heLa cells in the presence of transferrin or ferricyanide. Biochem Biophys Res Commun 135:110–115. CrossRefPubMedGoogle Scholar
  52. 52.
    Jagow GV, Link TA (1986) Use of specific inhibitors on the mitochondrial bc1 complex. Methods Enzymol 126:253–271. CrossRefGoogle Scholar
  53. 53.
    Ernster L, Dallner G, Azzone GF (1963) Differential effects of rotenone and amytal on mitochondrial electron energy transfer. J Biol Chem 238:1124–1131Google Scholar
  54. 54.
    Oberg KE (1961) The site of the action of rotenone in the respiratory chain. Exp Cell Res 24:163–164CrossRefGoogle Scholar
  55. 55.
    Yagi T (1990) Inhibition by capsaicin of NADH-quinone oxidoreductase is correlated with the presence of energy coupling site I in various organisms. Arch Biochem Biophys 21:305–311. CrossRefGoogle Scholar
  56. 56.
    Horgan DJ, Singer TP (1968) Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase: XII. Binding sites of rotenone, piericidin A, and amytal in the respiratory chain. J Biol Chem 243:834–843PubMedGoogle Scholar
  57. 57.
    Martin E, Mukkada AJ (1979) Identification of the terminal respiratory chain in kinetoplast mitochondrial complexes of Leishmania tropica promastigotes. J Biol Chem 254:12192–12198PubMedGoogle Scholar

Copyright information

© Witold Stefański Institute of Parasitology, Polish Academy of Sciences 2019

Authors and Affiliations

  1. 1.Department of PharmacyAtish Dipankar University of Science and TechnologyDhakaBangladesh
  2. 2.Animal and Plant Quarantine AgencyGimcheon-siRepublic of Korea
  3. 3.College of MedicineUniversity of South AlabamaMobileUSA
  4. 4.Division of Medicinal Biochemistry, Department of Pharmaceutical TechnologyJadavpur UniversityKolkataIndia

Personalised recommendations